Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

Fabry Disease Clinical Trial

Official title:

An Observational Study of Enzyme Replacement Therapy-Naïve and Agalsidase Beta-Treated Fabry Disease Patients With GLA IVS4 919 G>A Mutation in Taiwan

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06052800
• Other study ID #: OBS17349
• Secondary ID: U1111-1287-7177
• Status: Recruiting
• Start date: September 13, 2023
• Est. completion date: September 4, 2026

Study information

• Verified date: December 2023
• Source: Sanofi
• Contact: Trial Transparency email recommended (Toll free for US & Can
• Phone: 800-633-1610
• Email: Contact-US[@]sanofi.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This is a national, multicenter, observational, cohort study designed to assess clinical outcomes upon agalsidase beta treatment, to characterize the clinical manifestations, and to collect the natural history on male and female Fabry disease adult patients who carry the GLA IVS4. This study aims to retrospectively and prospectively investigate the disease natural history, clinical manifestations, and the treatment outcomes upon agalsidase beta in Fabry disease (FD) patients carrying the GLA IVS4 mutation from medical records, physician assessments, and patient-reported outcomes.

Description:

Study Design Time Perspective: Retrospective and Prospective

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: September 4, 2026
• Est. primary completion date: September 4, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provide signed informed consent.

Cohort 1:

• Male or female Fabry disease patient with documented GLA IVS4 in medical record.
• Age = 18 years old at the time of signing informed consent.
• The maximum proportion of female is 20% of cohort 1.
• Patient who has received agalsidase beta treatment for at least 6 months.
• The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months prior to agalsidase beta treatment initiation.

Cohort 2:

• Male or female Fabry disease patient with documented GLA IVS4 in medical record.
• Age = 18 years old at the time of signing informed consent.
• The maximum proportion of female is 20% of cohort 2.
• Patient who plans to apply for the National Health Insurance Reimbursement for agalsidase beta medication.
• The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months prior to agalsidase beta treatment initiation.

Cohort 3:

• Male or female Fabry disease patients with documented GLA IVS4 mutation in medical record.
• Male patient is aged = 30 years old and female patient is aged = 40 years old at the time of signing informed consent.
• The maximum proportion of female is 20% of cohort 3.
• Patient who has never received agalsidase alpha or agalsidase beta treatment (ERT-naïve).
• Elevated blood lyso-Gb3.
• At least ONE of the following conditions documented in medical record:

1. cardiac parameter abnormalities (e.g. via imaging, electrophysiology, or biomarker);

2. at least one FD-related sign/symptom.

• The data of LVMI, LPWT, IVST and blood lyso-Gb3 concentration are all available within 6 months.
• Patients who are expected not to receive ERT or FD-specific treatment per investigator's judgement.

Exclusion Criteria:

• Any condition that, in the opinion of the Investigator, may interfere with patient's participation in the study, such as life expectancy of less than 6 months (e.g. diagnosed with malignancy, CAD)
• Fabry patients who have severe heart disease (NYHA Class IV) or severe myocardial fibrosis per investigator judgement
• Known non-Fabry disease infiltrative cardiomyopathy including amyloidosis
• Known non-GLA genetic (e.g., sarcomeric, metabolic mutations) hypertrophic cardiomyopathy.
• Patients who are receiving any Fabry disease-specific treatment (enzyme replacement therapy, chaperone therapy, substrate reduction therapy, or gene therapy) other than agalsidase beta for Fabry disease
• Pregnancy or suspected pregnancy
• Patient diagnosed with moderate to severe dementia
• Unstable patient condition as judged by investigator (e.g., hypertension, diabetes, and systematic disease)

Related Conditions & MeSH terms

• Fabry Disease

Locations

Country	Name	City	State
Taiwan	Investigational Site Number :1580004	Taichung
Taiwan	Investigational Site Number :1580005	Tainan
Taiwan	Investigational Site Number :1580001	Taipei
Taiwan	Investigational Site Number :1580002	Taipei
Taiwan	Investigational Site Number :1580003	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cohort 1: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients		through study completion with a minimum of 2 years
Primary	Cohort 2: change of Left ventricular mass index (LVMI) as measured by echocardiography in agalsidase beta-treated patients		up to 1.5 years
Secondary	Change of Left posterior wall thickness (LPWT) as measured by echocardiography		For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years
Secondary	Change of Interventricular septal thickness (IVST) as measured by echocardiography		For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years
Secondary	Change of blood Globotriaosylsphingosine (lyso-Gb3) concentration		For cohort 1, through study completion with a minimum of 2 years For cohort 2, 1.5 years For cohort 3, through study completion with a minimum of 1.5 years
Secondary	Change of left ventricular mass index (LVMI) as measured by echocardiography in ERT-naive patients		For cohort 3, through study completion with a minimum of 1.5 years